1990. Neuropsychological deficits and CT scan changes in elderly depressives. Psychol Med
20, 507–20., and
1993. Serotonin 5-HT3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res
616, 53–7., , , et al.
2007. How can drug discovery for psychiatric disorders be improved?
Nat Rev Drug Discov
6, 189–201., , , et al.
1994. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry
27, 2–6. and
1991. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: A positron emission tomography study on patients and healthy volunteers. Acta Psychiatr Scand
83, 449–55., , , et al.
2000. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry
57, 285–90., , , et al.
1996. Disability in geriatric depression. Am J Psychiatry
153, 877–85., , , et al.
2001. Caudate nucleus dopamine D(2) receptors in depressed suicide victims. Neuropsychobiology
44, 70–3. and
2000. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry
157, 1108–14., , , et al.
1995. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res
688, 121–33., , and
2002. Serotonin brain circuits involved in major depression and suicide. Progr Brain Res
136, 443–53., and .
1997. Postmortem findings in suicide victims. Implications for in vivo imaging studies. Ann N Y Acad Sci
836, 269–87., and
1986. Improved delineation of human dopamine receptors using [18F]-N-methylspiroperidol and PET. J Nucl Med
27, 1878–82., , , et al.
1999. Review of community prevalence of depression in later life. Br J Psychiatry
174, 307–11., and
2002. The natural history of late-life depression: A 6-year prospective study in the community. Arch Gen Psychiatry
59, 605–11., , , et al.
1997a. Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol
24, 381–8., , and
1997b. 11C-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies. Nucl Med Biol
24, 287–93., and
2006. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: A positron emission study with [(11)C]MDL 100,907. Am J Psychiatry
163, 1580–7., , , , and
2007. 5-HTT binding in recovered depressed patients and healthy volunteers: A positron emission tomography study with [11C]DASB. Am J Psychiatry
164, 1858–65., , , et al.
1986. Characterization and localization ofserotonin receptors in human brain postmortem. Brain Res
363, 91–8., , and
1997. Serotonin 5-HT2 receptor imaging in major depression: Focal changes in orbito-insular cortex. Br J Psychiatry
171, 444–8., , , , and
1998. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry
44, 169–78., , , et al.
1990. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry
51 (Suppl), 14–20; discussion 21., and
1991. PET studies of [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. Neurosci Lett
121, 183–6., , , , and
1990. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem
54, 1744–54., , , et al.
1997. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res
752, 227–33., , , et al.
1989. Mania associated with high percentage of inhibition of monoamine oxidase. Am J Psychiatry
146, 121., and
2008. Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med
49, 2042–8., , , et al.
1993. Dopamine and depression. J Neural Transm
91, 75–109. and
1989. Psychiatric disorders and 15-month mortality in a community sample of older adults. Am J Public Hlth
79, 727–30. and
1993. SPECT imaging of dopamine and serotosin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neurol Transm Gen Sect
94, 137–46., , , , , and .
2000. Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: Assessment of methods. J Cerebr Blood Flow Metab
20, 253–62., , , et al.
1989. Dopamine receptors in human brain: Autoradiographic distribution of D2 sites. Neuroscience
28, 275–90., , , and
2006. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry
60, 207–17., , , et al.
2007. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry
62, 870–7., , , et al.
2009. Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology, 5, 1277–87., , , , and
1998. Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: Control and competition studies. J Cereb Blood Flow Metab
18, 1130–42., , , , and
2003. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science
301, 386–9., , , et al.
2004. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol Neurobiol
2006. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: A 123I-ADAM SPECT study. Psychopharmacology (Berl)
189, 145–53., , , et al.
1996. Radiosynthesis of [18F] N-3-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol
23, 999–1004., , , et al.
2008. Nuclear imaging of neuroinflammation: A comprehensive review of [(11)C]PK11195 challengers. Eur J Nucl Med Mol Imaging
35, 2304–19., , , and
1999. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol
409, 38–56., , , et al.
1999. Prognosis of depression in elderly community and primary care populations: A systematic review and meta-analysis. Am J Psychiatry
156, 1182–9., and
2006. In vivo evaluation and quantification of the 5-HT4 receptor PET ligand [11C]SB-207145. Neuroimage
31, T23., , , , and
1996. Relationships of age and axis I diagnoses in victims of completed suicide: A psychological autopsy study. Am J Psychiatry
153, 1001–08., , , , and
1988. Autoradiography of antidepressant binding sites in the human brain: Localization using [3H]imipramine and [3H]paroxetine. Neuroscience
27, 473–96., , , and
1996. Advances in psychopharmacology: Mood disorders and dementia. Br Med Bull
2002. Imaging cAMP-specific phosphodiesterase-4 in human brain with R-[(11)C]rolipram and positron emission tomography. Eur J Nucl Med Mol Imag
29, 1680–3., , , , and
2005. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci
25, 2586–90., , , et al.
2003. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med
44, 855–61., , , et al.
1990. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse
5, 213–23., , , et al.
1993. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse
13, 350–6., , , , and
1986. Cholinergic mechanisms in depression. Brain Res
2006. PET imaging of norepinephrine transporters. Curr Pharm Des
12, 3831–45., and
1999. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry
46, 1375–87., , , et al.
2000. Serotonin type-1A receptor imaging in depression. Nucl Med Biol
27, 499–507., , , , and
1997. A molecular and cellular theory of depression. Arch Gen Psychiatry
54, 597–606., and
1994. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation – Preliminary results. Biol Psychiatry
35, 880–5., , , and
2001. Radiolabeled muscarinic radioligands for in vivo studies. Nucl Med Biol
1984. External imaging of cerebral muscarinic acetylcholine receptors. Science
223, 291–3., , , et al.
2000. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. Faseb J
2005. Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: A SPECT validation study. Eur J Nucl Med Mol Imaging
32, 1329–36., , , et al.
1985. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA
82, 3863–7., , , et al.
1998. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med
39, 1965–71., , , and
1991. In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine, a possible ligand for positron emission tomography. Neuropharmacology
30, 899–905., , , et al.
1995. Structured Clinical Interview for DSM-IV-Non-Patient Edition (SCID-NP, Version 1.0)., Washington, D.C.: American Psychiatric Press., , and
1987. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science
235, 481–5., , , et al.
1993. Antemortem measurements of neurotransmission: Possible implications for pharmacotherapy of Alzheimer's disease and depression. J Neurol Neurosurg Psychiatry
56, 80–4., , , et al.
2005. Brain serotonin transporter distribution in subjects with impulsive aggressivity: A positron emission study with [11C]McN 5652. Am J Psychiatry
162, 915–23., , , et al.
2006. Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: Reproducibility and comparison of methods. J Nucl Med
47, 815–26., , , et al.
1996. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol
40, 873–84., , , et al.
2008. Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry
63, 569–76., , , et al.
2001. PET imaging of the opioid receptor: The early years. Nucl Med Biol
1993. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol
34, 423–31., , , et al.
1985. Imaging opiate receptors in the human brain by positron tomography. J Comp Assist Tomog
9, 231–6., , , et al.
2008. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage
40, 43–52., , , et al.
2006. Antidepressant efficacy of the antimuscarinic drug scopolamine: A randomized, placebo-controlled clinical trial. Arch Gen Psychiatry
63, 1121–9. and
1983. Dopamine visualized in the basal ganglia of living man. Nature
305, 137–8., and
2008. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: A preliminary study. J Clin Psychopharmacol
28, 340–4., , , and
2006. Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab
26, 330–44., ,
2001. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: Modeling strategies. J Cereb Blood Flow Metab
21, 1342–53., , , and
2002. Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab
22, 1453–62., , , et al.
1998. Whole hemisphere autoradiography of the postmortem human brain. Nucl Med Biol
25, 715–9., , and
1995. Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors. J Nucl Med
36, 1275–81., , , et al.
1998. Carbon-11-NNC 112: A radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med
39, 2061–8., , , et al.
2002. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry
2002. Serotonin in transporter genetic variation and the response of the human amygdala. Science
297, 400–3., , , et al.
1991. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography. J Neural Transm Gen Sect
86, 25–41., , , et al.
2008. [11C]CHIBA-1001 as a novel PET ligand for alpha7 nicotinic receptors in the brain: A PET study in conscious monkeys. PLoS ONE
3, e3231., , , et al.
2009. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging
36(Suppl 1), S105–12.
2006. Brain receptor imaging. J Nucl Med
47, 302–12. and
1995. Mental disorders in elderly suicide. Int Psychogeriatr
7, 275–86., , , et al.
2009. Measurement of central micro-opioid receptor binding in vivo with PET and [(11)C]carfentanil: A test–retest study in healthy subjects. Eur J Nucl Med Mol Imaging
36, 275–86., , , et al.
2008. Striatal dopamine D2 receptors in medication-naïve patients with major depressive disorder as assessed with [11C]raclopride PET. Psychopharmacology (Berl)
197, 581–90., , , et al.
2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology
2000. 6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci
67, 463–9., , , et al.
2000. Imaging the serotonin transporter with positron emission tomography: Initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med
27, 1719–22., , , and
1986a. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res
376, 85–96., , and
1986b. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res
376, 97–107., , and
2001. Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands. Bioorg Med Chem Lett
11, 1375–7., , , et al.
2000. (–)-N-[(11)C]propyl-norapomorphine: A positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol
27, 533–9., and
2002. Serotonin transporter binding in patients with mood disorders: A PET study with [11C](+)McN5652. Biol Psychiatry
51, 715–22., , , et al.
2002. Quantitative analysis for estimating binding potential of the brain serotonin transporter with [11 C]McN5652. J Cereb Blood Flow Metab
22, 490–501., , , et al.
1998. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J Nucl Med
39, 208–14., , , and
1989. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol
26, 752–8., , , et al.
1992. Role of the dopaminergic system in depression. Biol Psychiatry
32, 1–17. and
2010. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry
15, 473–500. and .
2007. Current issues in the classification of psychotic major depression. Schizophr Bull
33, 877–85., and
2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry
62, 617–27., , , and
1992. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol
223, 105–7., , , et al.
1994. Recent pharmacologic advances in antidepressant therapy. Am J Med
2006. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl)
188, 263–72., , , et al.
2007. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study. Psychopharmacology (Berl)
191, 333–9., , , et al.
2002. Dopaminergic abnormalities in amygdaloid nuclei in major depression: A postmortem study. Biol Psychiatry
52, 740–8., , , and
1999. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res
90, 91–101., , , , and
1999. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: Alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab
19, 1150–63., , , , and
1991. Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab
11, 735–44., , , and
2008. The molecular neurobiology of depression. Nature
455, 894–902. and
2004. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry
56, 497–502., , , et al.
2003. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology
28, 413–20., , , et al.
1994. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med
35, 405–10., , , et al.
1990. In vivo SPECT imaging of CNS D-2 dopamine receptors: Initial studies with iodine-123-IBZM in humans. J Nucl Med
31, 573–9., , , et al.
1999. Characterization of [(123)I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med
26, 844–53., , , , and
1994. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med
35, 743–54., , , et al.
2002. Structure–affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. J Med Chem
45, 5727–35., , , et al.
1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science
274, 1527–31., , , et al.
1990. Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacology
1998. A.E. Bennett research award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry
43, 547–73., , and
2000. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Progr Brain Res
128, 231–41. and
1996. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography. Life Sci
58, PL 187–92., , , et al.
1995. The serotonin hypothesis of major depression. In (ed.) Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, pp. 933–44. and
1998. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry
44, 1090–8., , , et al.
1999. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology
2000. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry
57, 729–38., , , et al.
1998. The electrophysiology of prefrontal serotonin systems: Therapeutic implications for mood and psychosis. Biol Psychiatry
44, 1118–27. and
2007. Quantification of 11C-SB207145-PET for 5-HT4 receptors in the human brain: Preliminary results. J Nucl Med Meeting Abstracts
48, 159P., , , et al.
2001. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol
28, 187–95., , , et al.
1997. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology
133, 99–101., , , et al.
2008. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology
33, 2080–92., and
2003. Synthesis and evaluation of (11)C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem
46, 2740–54., , , , and
2003. Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull
1989. Distribution of D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA
86, 7625–8., , , , and .
1999. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am J Psychiatry
156, 1871–8., , , et al.
2004. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology
29, 2258–65., , , et al.
1998. Serotonin in aging, late-life depression, and alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology
18, 407–30., , , et al.
1990. Localization of the mRNA for the 5-HT2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res
524, 139–43., , and
2007. Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry
64, 543–52., , , et al.
2001. SPECT and neuropsychological performance in severe depression treated with ECT. J Affect Disord
66, 47–58., , , et al.
2003. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: A PET study. Psychopharmacology
167, 72–8., , , et al.
2007. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci
1999a. The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology
144, 279–81., , and
2006. Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry
63, 1209–16., , , et al.
2004. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: Effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry
61, 1271–9., , , et al.
1999b. Prefrontal cortex 5-HT2 receptors in depression: An [18F]setoperone PET imaging study. Am J Psychiatry
156, 1029–34., , , et al.
2001a. Lower dopamine transporter binding potential in striatum during depression. Neuroreport
12, 4121–5., , , et al.
2003. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry
160, 90–9., , , et al.
2001b. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am J Psychiatry
158, 1843–9., , , et al.
2008. Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor in vivo with PET. J Nucl Med
49, 587–96., , , et al.
2008. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatric Res
42, 1137–44., , , and
2006. Correction of head movement on PET studies: Comparison of methods. J Nucl Med
47, 1936–44., , , , and
2000. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP in drug naive depressed patients: A PET study. Neuroimage
12, 452–65., , , et al.
2008. Serotonin 1A receptor reductions in postpartum depression: A positron emission tomography study. Fertil Steril
89, 685–92., , , et al.
2002. Brain imaging of 18F-fallypride in normal volunteers: Blood analysis, distribution, test–retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse
46, 170–88., , , et al.
1992. Imaging muscarinic cholinergic receptors in human brain in vivo with Spect, [123I]4-iododexetimide, and [123I]4-iodolevetimide. J Cereb Blood Flow Metab
12, 562–70., , , and
2008. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y(5) receptor and development of a novel Y(5)-selective radioligand. Eur J Pharmacol
601, 1–7., , , et al.
1996. Rethinking DALYs. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston, MA:
Harvard School of Public Health.
2002. Small animal PET. Eur Neuropsychopharmacol
12, 545–55. and
2006. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry
59, 1151–9. and
2005. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: A preliminary study. J Nucl Med
46, 973–7., , , et al.
1999a. Serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging. Brain Res
30, 250–63., and
1999b. Cerebral blood flow and metabolism in late-life depression and dementia. J Geriatric Psychiatry Neurol
12, 118–27., and
2006. Psychological, neuroimaging, and biochemical studies on functional association between impulsive behavior and the 5-HT2A receptor gene polymorphism in humans. Ann N Y Acad Sci
1086, 134–43. and
1995. Kinetic analysis of regional (S) (–)11C-nicotine binding in normal and Alzheimer brains – in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord
9, 21–7., , , and
2002. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry
159, 1855–61. and
2000. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan. J Psychiatry Neurosci
5, 359–70., , , and
2007. Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry
64, 201–08., , , et al.
1994. Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter. Clin Chem
40, 288–95. and
1996. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem
67, 876–9., , , et al.
2008. Evaluation of the novel 5-HT6 receptor radioligand, [11C]GSK-215083 in human. Neuroimage
41, T20., , , et al.
2006a. Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry
163, 52–8., , , et al.
2000. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med
41, 1465–77., , , et al.
2006b. Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry
59, 821–8., , , et al.
2006c. Altered serotonin 1A binding in major depression: A [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry
59, 106–13., , , et al.
2002. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res
954, 173–82., , , et al.
2001. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry
50, 313–22., , , et al.
1987. Serotonin receptors in the human brain – III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience
21, 97–122., and
1995. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry
52, 471–7., , , et al.
1995. 5-HT receptors: Past, present and future. Trends Neurosci
2008. [11C]AZ10419369: A selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage
41, 1075–85., , , et al.
2008. Ketones and brain function: Possible link to polyunsaturated fatty acids and availability of a new brain PET tracer, 11C-acetoacetate. Epilepsia
49 (Suppl 8), 76–9., , , , and
2003. Radioiodinated SB 207710 as a radioligand in vivo: Imaging of brain 5-HT4 receptors with SPET. Eur J Nucl Med Mol Imaging
30, 1520–8., , , et al.
1996. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol
301, R5–7., , , et al.
2000. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med
41, 36–44., , , et al.
2003. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse
48, 39–44., , , et al.
2007. Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine. Psychiatry Res
156, 251–5., , , et al.
2002. Evidence of increased serotonin-1A receptor binding in type 2 diabetes: A positron emission tomography study. Brain Res
927, 97–103., , , et al.
2009. A framework for interpreting genome-wide association studies of psychiatric disorders. Mol Psychiatry
2008. Accurate event-driven motion compensation in high-resolution PET incorporating scattered and random events. IEEE Trans Med Imaging
27, 1018–33., , , et al.
2006. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol
27, 24–31., and
2008. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostagland Leukot Essen Fatty Acids
1990. Cortisol and growth hormone responses to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry
28, 73–8., and
2008. Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET. Nucl Med Biol
35, 287–98., , , et al.
2008. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: A [11C]DASB PET study. Mol Psychiatry
13, 606–13, 557., , , et al.
2007. Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nature Neurosci
10, 1116–24. and
2006. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology
31, 1016–26., , , et al.
2008. Small animal PET in preclinical studies: Opportunities and challenges. Q J Nucl Med Mol Imaging
52, 215–21., , and
2004. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry
61, 556–63., , , et al.
2008. Design and implementation of an automated partial volume correction in PET: Application to dopamine receptor quantification in the normal human striatum. J Nucl Med
49, 1097–106., , and
2008. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med
38, 209–22. and
2007. Binding kinetics of 123I[ADAM] in healthy controls: A selective SERT radioligand. Int J Neuropsychopharmacol
10, 211–8., , , et al.
2000. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: Effects of depression and antidepressant treatment. Arch Gen Psychiatry
57, 174–80., , , et al.
1990. 3-(2'-[18F]fluoroethyl)spiperone, a potent dopamine antagonist: synthesis, structural analysis and in-vivo utilization in humans. Int J Radiat App Instrument – Part A, Appl Radiat Isotopes
41, 113–29., , , , and
1994. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. Neurochem Int
25, 503–32. and
2002. Brain imaging in affective disorders: More questions about causes versus effects. Am J Psychiatry
1983. Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res
276, 231–5., and
2007. Development of radioligands for imaging of brain norepinephrine transporters in vivo with positron emission tomography. Curr Top Med Chem
7, 1806–16., and
2003. A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology
28, 397–401., , , et al.
1988. McN-5652: A highly potent inhibitor of serotonin uptake. J Pharmacol Exp Therap
247, 1032–8., , , , and
2009. Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage
44, 340–8., , , et al.
2003. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse
48, 184–8., , , et al.
1997a. P-[18F]-MPPF: A potential radioligand for PET studies of 5-HT1A receptors in humans. Synapse
25, 147–54., , , et al.
1997b. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol
24, 145–50., , , et al.
2002. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriat Psychiatry
10, 24–35., , , et al.
1997. Subcortical vascular disease in elderly patients with treatment resistant depression. J Neurol Neurosurg Psychiatry
62, 196–7., , and
1997. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects. Am J Psychiatry
154, 490–6., , , et al.
2008. Serotonin transporter occupancy by citalopram treatment in geriatric depression. Neuroimage
41, T168., , , et al.
2009a. Serotonin modulation of cerebral glucose metabolism in geriatric depression. Biol Psychiatry
66, 259–66., , , et al.
2009b. The functional neuroanatomy of geriatric depression. Int J Geriatric Psychiatry
24, 798–808., , , et al.
2004. The effect of serotonin transporter polymorphisms on serotonin function. Neuropsychopharmacology
29, 2226–34., , , et al.
1998. Test–retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain. Synapse
30, 380–92., , , et al.
2007. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology
32, 1857–75., , , and
2009. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography. Synapse
63, 1–6., , , and
1999. Quantification of delta-opioid receptors in human brain with N1'-([11C]methyl) naltrindole and positron emission tomography. J Cereb Blood Flow Metab
19, 956–66., , , et al.
2005. Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci
25, 836–42., , , et al.
1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature
347, 146–51., , , and
2008. A new 18F-labeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. Nucl Med Biol
35, 185–95., , , et al.
1990. Direct immunohistochemical evidence of the existence of 5-HT1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci
2, 1144–54., , , and
2005. 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: Feasibility and reproducibility. J Nucl Med
46, 1466–72., , , et al.
2008. Radiolabeled glucocorticoids as molecular probes for imaging brain glucocorticoid receptors by means of positron emission tomography (PET). Mini Rev Med Chem
8, 728–39., , , and
2008. Synthesis and preliminary evaluation of [(18)F]-fluoro-(2S)-exaprolol for imaging cerebral beta-adrenergic receptors with PET. Neurochem Int
53, 173–9., , , , and
2003. Involvement of serotonin in depression: Evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatric Res
1996. Quantitative subregional distribution of serotonin1A receptors and serotonin transporters in the human dorsal raphe. Brain Res
727, 1–12., , , and
2003. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain
126, 2609–15., , and
2005. Electroconvulsive shock decreases binding to 5-HT2 receptors in nonhuman primates: An in vivo positron emission tomography study with [18F]setoperone. Biol Psychiatry
57, 1004–10., , and
1993. A PET radiotracer for studying serotonin uptake sites: Carbon-11-McN-5652Z. J Nucl Med
34, 120–7., , , , and
1991. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology
103, 41–5., , , et al.
2008. Neuroimaging in dementia: In vivo amyloid imaging. Tohoku J Exp Med
215, 119–24., and
1993. Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett
149, 225–8., , , and
1992. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology
106, 14–8., , , et al.
2007. PET imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density?
Nucl Med Biol
34, 353–61., , , et al.
2007. Synthesis of two potential NK1-receptor ligands using [1–11C]ethyl iodide and [1–11C]propyl iodide and initial PET-imaging. BMC Med Imaging
7, 6., , , , and
1995. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse
20, 37–43., , , et al.
2002. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med
43, 678–92., , , et al.
2007. Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry
62, 588–92., , , , and
2008. Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging
35, 153–7., , , et al.
2001. Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: A [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry
158, 1326–8., , , , and
1996. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl)
126, 277–80., , , et al.
1987. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites. Drug Metab Disposition: Biol Fate Chem
15, 74–81. and
2003. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J Affect Disord
74, 149–58., , , et al.
1991. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature
350, 610–4., , , et al.
2004. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Human Brain Mapp
22, 246–60., and
2008. Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide. Bioorg Med Chem
16, 5277–84., , , et al.
2004. In-vivo imaging of alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry
12, 584–95., , , et al.
1997. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog. J Nucl Med
38, 1737–41., , , et al.
1995. A new PET ligand for the dopamine transporter: Studies in the human brain. J Nucl Med
36, 2162–8., , , et al.
1996. PET evaluation of the dopamine system of the human brain. J Nucl Med
37, 1242–56., , , et al.
1994. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse
16, 255–62., , , et al.
1983. Imaging dopamine receptors in the human brain by positron tomography. Science
221, 1264–6., , , et al.
1996. Cross-national epidemiology of major depression and bipolar disorder. JAMA
276, 293–9., , , et al.
2006. High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry
59, 389–94., , , et al.
2000. [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry
47, 482–9., , , et al.
2001. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry
50, 8–12., , , et al.
2008. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol
35, 305–14., , , et al.
2002. In vitro and in vivo characterisation of [11C]-DASB: A probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nucl Med Biol
29, 509–15., , , and
2009. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology
34, 187–203., and
1984. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science
226, 1393–6., , , et al.
2008. Dopamine receptor gene expression in human amygdaloid nuclei: Elevated D4 receptor mRNA in major depression. Brain Res
1207, 214–24., , , et al.
2008. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry
64, 835–41., , , et al.
2007. PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: Assessment of reference tissue models and their test–retest reproducibility. Synapse
61, 242–51., , , et al.
1999. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: A positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry
56, 705–11., , , et al.
2002b. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry
159, 1718–23., , , et al.
2000. Brain serotonin 2 receptors in major depression: A positron emission tomography study. Arch Gen Psychiatry
57, 850–8., , , et al.
2002a. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: Effects of treatment with divalproex sodium. Am J Psychiatry
159, 768–74., , , et al.
2002. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry
7, 1115–9., , , and
2006. Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry
59, 1006–20. Jr, and
1992. Pharmacokinetics of the SPECT benzodiazepine receptor radioligand [123I]iomazenil in human and non-human primates. Int J Radiat Applic Instrum – Part B, Nucl Med Biol
19, 881–8., , , et al.
2003. Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Arch Gen Psychiatry
60, 1145–53., , , et al.
2001a. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science (New York, NY)
293, 311–5., , , et al.
2001b. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry
49, 110–6., , , , and